First Trust Advisors LP Has $1.51 Million Stake in Charles River Laboratories International, Inc. $CRL

First Trust Advisors LP grew its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 44.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,736 shares of the medical research company’s stock after buying an additional 2,689 shares during the period. First Trust Advisors LP’s holdings in Charles River Laboratories International were worth $1,507,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in CRL. Los Angeles Capital Management LLC acquired a new stake in Charles River Laboratories International in the 4th quarter worth approximately $42,000. Sfam LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth $43,000. Activest Wealth Management lifted its stake in shares of Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after buying an additional 218 shares during the last quarter. Elyxium Wealth LLC bought a new stake in shares of Charles River Laboratories International during the 4th quarter worth $46,000. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at $7,109,100. The trade was a 70.36% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 5,046 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the completion of the transaction, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,264,241. This represents a 51.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $266.95 on Monday. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $268.00. The company has a market capitalization of $12.74 billion, a P/E ratio of -55.04, a P/E/G ratio of 2.77 and a beta of 1.38. The stock has a 50 day moving average of $214.85 and a two-hundred day moving average of $189.04. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.Charles River Laboratories International’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 11.35 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CRL. Weiss Ratings upgraded shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Barclays restated an “overweight” rating and set a $300.00 price target on shares of Charles River Laboratories International in a report on Wednesday. CLSA downgraded Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research report on Monday, July 20th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Finally, BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a research report on Wednesday, July 1st. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $246.69.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.